nivolumab (Opdivo) -

nivolumab (Opdivo)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Skin disorders
Summary
Following a resubmission, assessed under the end of life and orphan medicine process nivolumab is accepted for restricted use within NHS Scotland. as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.
UKMi comment
Use is restricted to patients previously untreated with ipilimumab.

NICE TA384 recommends nivolumab as monotherapy as an option for treating advanced (unresectable or metastatic) melanoma in adults.
Related links: NICE TA384